TransMedics Group enters the post-earnings stretch with a battered share price and a wave of sharply lower analyst price targets rewriting the bull case.
The catalyst was immediate. The stock fell 6.3% on the week to $94.93, giving back roughly 5.7% over the past month as well. Earnings landed May 5, and the Street's response was swift and unambiguous — four separate analyst target cuts arrived on May 6 alone. The message is consistent: the thesis is intact, but the numbers need resetting.
That analyst reaction tells the story this week. TD Cowen slashed its target from $190 to $120 while holding a Buy. Piper Sandler cut from $160 to $120, maintaining Overweight. Needham trimmed from $174 to $142, keeping Buy. Stifel moved in the same direction but from a more cautious starting point — Hold, with a new target of $85 against a prior $130. The mean analyst target across the coverage group now sits at $123.60, which still implies roughly 30% upside from current levels, but that headline number reflects a cluster of targets that were anchored far higher just weeks ago. Bulls still dominate the ratings distribution; the debate is now over how much the growth re-rating is already priced into the pull-back.
Short positioning amplifies the interest here. With 22.6% of the free float estimated short, TMDX carries one of the heavier short burdens in the medical device space — ranked in just the 2nd percentile on ORTEX's short-score rank, meaning shorts are more crowded here than almost anywhere else in the universe. The ORTEX short score itself reads 76.6, consistent with the past two weeks. Importantly, though, short interest has been easing rather than building — down roughly 6.6% over the past month and off its late-March peak of around 8.4 million shares. Days to cover stands at 10.3 (FINRA, April 15 settlement), reflecting thin liquidity against a large short base. Cost to borrow is actually loosening, now at 0.42% — down 8.5% on the week and 13% over the month — suggesting borrow demand is not accelerating. Availability in the lending pool is moderate; roughly half of available shares are currently lent out against the 52-week peak of 52.9%, meaning there's no acute squeeze pressure building despite the elevated short count.
Options traders have moved more defensively over the past two weeks. The put/call ratio is running at 0.74 — up sharply from the 0.42–0.46 range that prevailed through mid-April — and is about 1.25 standard deviations above its 20-day average of 0.57. That's approaching but not yet at the year's high of 0.78, which hit on May 4. The shift is clear: since late April, hedging demand has risen materially. It's consistent with investors protecting gains (or limiting further downside) rather than reaching aggressively for recovery exposure.
The fundamental setup is not without its support. The bull case rests on OCS platform expansion and a 20–25% revenue growth guide, with consensus revenue estimates around $734 million and EBITDA near $168 million. On a trailing P/E of 33x and EV/EBITDA of 17.5x — both compressing over the past month — the valuation is cheaper than it was, though still demands execution. Goldman Sachs Asset Management added 441,000 shares in Q1, and T. Rowe Price built its position by nearly 172,000 shares in the same period, providing a degree of institutional conviction behind the recent weakness. The founder and CEO, Waleed Hassanein, trimmed 52,000 shares in Q1 but still holds a 1.6% stake — worth monitoring but not unusual in the context of planned selling.
The next scheduled event is May 20 — either a further update or a catalyst that resets the short thesis in one direction. With shorts still heavy, options tilted defensive, and analysts recalibrating targets in real time, the May 20 print becomes less about whether TransMedics is growing and more about whether the new, lower expectations bar has been set conservatively enough to allow a positive surprise.
See the live data behind this article on ORTEX.
Open TMDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
